Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
| ▸ | PLEC | Q15149 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243158 | 0.81 | L3MBTL1 (0.45) | L3MBTL1EPHX2KMT2ACYP2D6MAPT | |
| SCHEMBL7246773 | 0.79 | P2RX4 (0.62) | KMT2AP2RX4CACNA1B | |
| SCHEMBL7240658 | 0.68 | HTT (0.54) | L3MBTL1KMT2APOLBCACNA1BAPBA1 | |
| SCHEMBL3370719 | 0.67 | POLB (0.59) | L3MBTL1EPHX2KMT2APOLBCACNA1B | |
| SCHEMBL6918970 | 0.67 | L3MBTL1 (0.53) | L3MBTL1EPHX2KMT2APOLBMAPT | |
| SCHEMBL7242081 | 0.67 | HTT (0.57) | L3MBTL1KMT2APOLBCACNA1BAPBA1 | |
| SCHEMBL28192657 | 0.66 | L3MBTL1 (0.55) | L3MBTL1EPHX2KMT2AMAPTRAB9A | |
| SCHEMBL447082 | 0.66 | L3MBTL1 (0.51) | L3MBTL1EPHX2KMT2APOLBRAB9A | |
| SCHEMBL11704238 | 0.62 | ALDH1A1 (0.56) | L3MBTL1EPHX2KMT2AMAPTRAB9A | |
| SCHEMBL1416715 | 0.62 | RPS6KA2 (0.47) | L3MBTL1EPHX2KMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049330-A1 | Novel pyridones and their use as modulators of serine hydrolase enzymes | DALHOUSIE UNIVERSITY | 2002-04-25 | — | — | US | claimed |
| US-6544986-B2 | Such as 5-(N,N-dibenzyl)aminocarbonyl-2-pyridone; enzyme inhibitors; for treatment of Alzheimer's disease | DALHOUSIE UNIVERSITY (CA) | 2003-04-08 | — | — | US | disclosed |
| US-6436972-B1 | HETEROCYCLIC AMIDES, USED AS ANTICHOLINERGICS AND SERINE PROTEASE STIMULANTS, FOR PROPHYLAXIS OF ALZHEIMER'S DISEASE, GLIOMAS AND VISION DEFECTS | DALHOUSIE UNIVERSITY (CA) | 2002-08-20 | — | — | US | disclosed |
| US-20020049330-A1 | Novel pyridones and their use as modulators of serine hydrolase enzymes | DALHOUSIE UNIVERSITY | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049330-A1 | Novel pyridones and their use as modulators of serine hydrolase enzymes | BCHE, PRSS1, BACE1 | L3MBTL1 3683/4885EPHX2 306/4885KMT2A 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.